Literature DB >> 20592421

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Hege G Russnes1,2,3, Hans Kristian Moen Vollan1,3,4, Ole Christian Lingjærde5, Alexander Krasnitz6, Pär Lundin7, Bjørn Naume8, Therese Sørlie1, Elin Borgen2, Inga H Rye2, Anita Langerød1, Suet-Feung Chin9, Andrew E Teschendorff9,10, Philip J Stephens11, Susanne Månér7, Ellen Schlichting4, Lars O Baumbusch1,2,5, Rolf Kåresen4, Michael P Stratton11,12, Michael Wigler6, Carlos Caldas9,13, Anders Zetterberg7, James Hicks6, Anne-Lise Børresen-Dale1,3.   

Abstract

Distinct molecular subtypes of breast carcinomas have been identified, but translation into clinical use has been limited. We have developed two platform-independent algorithms to explore genomic architectural distortion using array comparative genomic hybridization data to measure (i) whole-arm gains and losses [whole-arm aberration index (WAAI)] and (ii) complex rearrangements [complex arm aberration index (CAAI)]. By applying CAAI and WAAI to data from 595 breast cancer patients, we were able to separate the cases into eight subgroups with different distributions of genomic distortion. Within each subgroup data from expression analyses, sequencing and ploidy indicated that progression occurs along separate paths into more complex genotypes. Histological grade had prognostic impact only in the luminal-related groups, whereas the complexity identified by CAAI had an overall independent prognostic power. This study emphasizes the relation among structural genomic alterations, molecular subtype, and clinical behavior and shows that objective score of genomic complexity (CAAI) is an independent prognostic marker in breast cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20592421      PMCID: PMC3972440          DOI: 10.1126/scitranslmed.3000611

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  66 in total

1.  The Stability of Broken Ends of Chromosomes in Zea Mays.

Authors:  B McClintock
Journal:  Genetics       Date:  1941-03       Impact factor: 4.562

2.  Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.

Authors:  Michael T Barrett; Alicia Scheffer; Amir Ben-Dor; Nick Sampas; Doron Lipson; Robert Kincaid; Peter Tsang; Bo Curry; Kristin Baird; Paul S Meltzer; Zohar Yakhini; Laurakay Bruhn; Stephen Laderman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

3.  Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma.

Authors:  G Forsslund; A Zetterberg
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

Authors:  F Courjal; M Cuny; J Simony-Lafontaine; G Louason; P Speiser; R Zeillinger; C Rodriguez; C Theillet
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

5.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Authors:  G Wiedswang; E Borgen; R Kåresen; G Kvalheim; J M Nesland; H Qvist; E Schlichting; T Sauer; J Janbu; T Harbitz; B Naume
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

6.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Authors:  Bjørn Naume; Xi Zhao; Marit Synnestvedt; Elin Borgen; Hege Giercksky Russnes; Ole Christian Lingjaerde; Maria Strømberg; Gro Wiedswang; Gunnar Kvalheim; Rolf Kåresen; Jahn M Nesland; Anne-Lise Børresen-Dale; Therese Sørlie
Journal:  Mol Oncol       Date:  2007-04-04       Impact factor: 6.603

7.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.

Authors:  Jorge S Reis-Filho; Kay Savage; Maryou B K Lambros; Michelle James; Dawn Steele; Robin L Jones; Mitch Dowsett
Journal:  Mod Pathol       Date:  2006-04-28       Impact factor: 7.842

8.  Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.

Authors:  Tarek M A Abdel-Fatah; Desmond G Powe; Zsolt Hodi; Jorge S Reis-Filho; Andrew H S Lee; Ian O Ellis
Journal:  Am J Surg Pathol       Date:  2008-04       Impact factor: 6.394

9.  Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?

Authors:  Rachael Natrajan; Maryou B K Lambros; Felipe C Geyer; Caterina Marchio; David S P Tan; Radost Vatcheva; Kai-Keen Shiu; Daniela Hungermann; Socorro Maria Rodriguez-Pinilla; Jose Palacios; Alan Ashworth; Horst Buerger; Jorge S Reis-Filho
Journal:  Genes Chromosomes Cancer       Date:  2009-04       Impact factor: 5.006

10.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  80 in total

1.  Genomics: A broad brush.

Authors:  Nicola McCarthy
Journal:  Nat Rev Cancer       Date:  2010-09       Impact factor: 60.716

2.  Assessment of palindromes as platforms for DNA amplification in breast cancer.

Authors:  Jamie Guenthoer; Scott J Diede; Hisashi Tanaka; Xiaoyu Chai; Li Hsu; Stephen J Tapscott; Peggy L Porter
Journal:  Genome Res       Date:  2011-07-13       Impact factor: 9.043

3.  Target inference from collections of genomic intervals.

Authors:  Alexander Krasnitz; Guoli Sun; Peter Andrews; Michael Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

Review 4.  Systems biology and genomics of breast cancer.

Authors:  Charles M Perou; Anne-Lise Børresen-Dale
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

Review 5.  Principles and methods of integrative genomic analyses in cancer.

Authors:  Vessela N Kristensen; Ole Christian Lingjærde; Hege G Russnes; Hans Kristian M Vollan; Arnoldo Frigessi; Anne-Lise Børresen-Dale
Journal:  Nat Rev Cancer       Date:  2014-05       Impact factor: 60.716

6.  Enhancing sensitivity and specificity in rare cell capture microdevices with dielectrophoresis.

Authors:  James P Smith; Chao Huang; Brian J Kirby
Journal:  Biomicrofluidics       Date:  2015-02-10       Impact factor: 2.800

Review 7.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

8.  The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.

Authors:  Kristine Kleivi Sahlberg; Vesa Hongisto; Henrik Edgren; Rami Mäkelä; Kirsi Hellström; Eldri U Due; Hans Kristian Moen Vollan; Niko Sahlberg; Maija Wolf; Anne-Lise Børresen-Dale; Merja Perälä; Olli Kallioniemi
Journal:  Mol Oncol       Date:  2012-11-24       Impact factor: 6.603

Review 9.  What are we learning from the cancer genome?

Authors:  Eric A Collisson; Raymond J Cho; Joe W Gray
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

Review 10.  Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.

Authors:  Vida Pourteimoor; Samira Mohammadi-Yeganeh; Mahdi Paryan
Journal:  Tumour Biol       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.